Patents by Inventor John A. Katzenellenbogen

John A. Katzenellenbogen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10703698
    Abstract: Provided are compounds of formulae provided herein. The compounds may include pathway-preferential estrogens (PaPEs) derivatives with tissue-selective activities. Also provided are pharmaceutical compositions comprising the compounds, as well as methods of treating a disease or condition including administering the compounds. The disease or condition may include postmenopausal symptoms, cardiovascular disease, stroke, vascular disease, bone disease, metabolic disease, arthritis, osteoporosis, obesity, vasomotor/hot flush, cognitive decline, cancer including breast cancer.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: July 7, 2020
    Assignees: The Board of Trustees of the University of Illinois, Board of Regents of the University of Texas System
    Inventors: John A. Katzenellenbogen, Benita Katzenellenbogen, Sung Hoon Kim, Zeynep Madak-Erdogan, Philip Shaul
  • Publication number: 20190002380
    Abstract: Provided are compounds of formulae provided herein. The compounds may include pathway-preferential estrogens (PaPEs) derivatives with tissue-selective activities. Also provided are pharmaceutical compositions comprising the compounds, as well as methods of treating a disease or condition including administering the compounds. The disease or condition may include postmenopausal symptoms, cardiovascular disease, stroke, vascular disease, bone disease, metabolic disease, arthritis, osteoporosis, obesity, vasomotor/hot flush, cognitive decline, cancer including breast cancer.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 3, 2019
    Inventors: John A. Katzenellenbogen, Benita Katzenellenbogen, Sung Hoon Kim, Zeynep Madak-Erdongan, Philip Shaul
  • Publication number: 20180303807
    Abstract: Described are compounds that inhibit androgen receptor action, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Application
    Filed: October 1, 2016
    Publication date: October 25, 2018
    Inventors: John A. Katzenellenbogen, Jatinder Josan, John Norris, Donald P. McDonnell
  • Patent number: 9868705
    Abstract: The present disclosure provides tetra-substituted cyclobutane inhibitors of Androgen Receptor Action, and methods of using such inhibitors, for the treatment of hormone-refractory cancers.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: January 16, 2018
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, DUKE UNIVERSITY
    Inventors: John Katzenellenbogen, Donald McDonnell, John D. Norris, Alexander Parent, Julie Pollock, Jillian Gunther, Kathryn E. Carlson, Teresa Martin
  • Patent number: 9448173
    Abstract: The invention provides dendrimers, conjugates thereof, and methods of using dendrimer conjugates. In one embodiment, the invention provides novel polymeric dendrimers as a new class of fluorescent labels. The labels can include multiple fluorescent dye molecules conjugated to a single polymeric backbone or core, such as a dendrimer. The dendrimers can have regular or irregular branched polymeric network structures that allow for the chemical attachment of multiple dye molecules, multiple color dyes, and/or multiple functional groups, in a combinatorial fashion. The fluorescent dendritic nanoprobes (FDNs) thus provide a new class of fluorescent reporters for fluorescence microscopy and imaging.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: September 20, 2016
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Younghoon Kim, Sung Hoon Kim, Melikhan Tanyeri, John A. Katzenellenbogen, Charles M. Schroeder, III
  • Patent number: 9273115
    Abstract: The present invention relates to a method for tightly temporally controlling the biological activity of a protein of interest in a vertebrate, upon induction of the activity of a fusion protein comprising said protein of interest and an ERM polypeptide containing a mutated ligand binding domain of the human oestrogen receptor ?, with a synthetic ligand that does not interfere with oestrogen signalling. In particular, the present invention concerns a method for generating tightly temporally-controlled targeted somatic mutations in a vertebrate, preferably a mouse, by inducing the activity of a fusion protein comprising a site-specific recombinase protein and an ERM polypeptide, with a synthetic ligand devoid of oestrogenic and anti-oestrogenic activities.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: March 1, 2016
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, UNIVERSITE DE STRASBOURG
    Inventors: Daniel Metzger, Pierre Chambon, Huimin Zhao, John Katzenellenbogen
  • Publication number: 20120256102
    Abstract: The invention provides dendrimers, conjugates thereof, and methods of using dendrimer conjugates. In one embodiment, the invention provides novel polymeric dendrimers as a new class of fluorescent labels. The labels can include multiple fluorescent dye molecules conjugated to a single polymeric backbone or core, such as a dendrimer. The dendrimers can have regular or irregular branched polymeric network structures that allow for the chemical attachment of multiple dye molecules, multiple color dyes, and/or multiple functional groups, in a combinatorial fashion. The fluorescent dendritic nanoprobes (FDNs) thus provide a new class of fluorescent reporters for fluorescence microscopy and imaging.
    Type: Application
    Filed: March 8, 2012
    Publication date: October 11, 2012
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Younghoon Kim, Sung hoon Kim, Melikhan Tanyeri, John A. Katzenellenbogen, Charles M. Schroeder, III
  • Publication number: 20120052570
    Abstract: The present invention relates to a method for tightly temporally controlling the biological activity of a protein of interest in a vertebrate, upon induction of the activity of a fusion protein comprising said protein of interest and an ERM polypeptide containing a mutated ligand binding domain of the human oestrogen receptor ?, with a synthetic ligand that does not interfere with oestrogen signalling. In particular, the present invention concerns a method for generating tightly temporally-controlled targeted somatic mutations in a vertebrate, preferably a mouse, by inducing the activity of a fusion protein comprising a site-specific recombinase protein and an ERM polypeptide, with a synthetic ligand devoid of oestrogenic and anti-oestrogenic activities.
    Type: Application
    Filed: January 22, 2010
    Publication date: March 1, 2012
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURG, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Daniel Metzger, Pierre Chambon, Huimin Zhao, John Katzenellenbogen
  • Publication number: 20070021495
    Abstract: Compounds, pharmaceutically acceptable salts, stereoisomers and prodrugs thereof, that are ER ligands and particularly to such compounds that are ER beta-selective and/or ER beta-specific ligands. Compounds herein include certain compounds which are ER beta-selective agonists. Compounds herein include ER beta-selective agonists which exhibit minimal agonist or antagonist effect on ER alpha. Compounds of the invention include those of formula I: and any pharmaceutically acceptable salts, stereoisomers and prodrugs thereof wherein AR, R1, R3, and X1—X4 are as defined hereinabove.
    Type: Application
    Filed: July 25, 2006
    Publication date: January 25, 2007
    Inventors: John Katzenellenbogen, Benita Katzenellenbogen, Dennis Compton
  • Publication number: 20030119800
    Abstract: A variety of bone anabolic compounds are useful for maintaining and/or increasing bone mass, density, and/or strength in mammals. Preferred compounds enhance bone anabolic activity while minimizing or eliminating undesirable feminizing or masculinizing effects.
    Type: Application
    Filed: June 7, 2002
    Publication date: June 26, 2003
    Inventors: Stavros C. Manolagas, John A. Katzenellenbogen
  • Patent number: 4851402
    Abstract: Estriol is administered to ruminants in dosages from about 0.01-4.0 mg/ruminant/day to promote growth and increase feed utilization efficiency.
    Type: Grant
    Filed: February 27, 1987
    Date of Patent: July 25, 1989
    Assignee: International Minerals & Chemical Corp.
    Inventors: Martin J. Jacobs, John Katzenellenbogen
  • Patent number: 4064150
    Abstract: Aliphatic acids containing an isoprenoid 1,5-diene moiety are prepared in high yields by the selective gamma alkylation of .alpha.,.beta.-unsaturated acids with allylic electrophiles. The gamma-regioselectivity of the alkylation is controlled by the use of the dicopper(I) dienolates prepared from the .alpha.,.beta.-unsaturated acids. The method offers a particularly facile means for synthesizing isoprenoid 1,5-diene natural products such as farnesoic acid by alkylation of senecioic acid with geranyl bromide; geranoic acid by alkylation of senecioic acid with 3,3-dimethallyl bromide; and dl-lanceol by alkylation of tiglic acid with an allylic bromide derived from dl-limonene. Such products find use in the synthesis of insect pheremones, insect juvenile hormones, and components of perfumes.
    Type: Grant
    Filed: May 26, 1976
    Date of Patent: December 20, 1977
    Assignee: University of Illinois Foundation
    Inventor: John A. Katzenellenbogen